On May 5, 2026, Arista Networks (ANET) released its Q1 2026 results, Q2 outlook, and revised FY2026 guidance. The Q1 revenue and operating margin came in ahead of guidance and management raised its full-year outlook for total revenue and artificial intelligence revenue. Despite decent results and guidance, ANET's share price softened so I acquired an [...]
I last reviewed Ecolab Inc. (ECL) in a February 24, 2022 guest post at Dividend Power. I subsequently sold: 96 shares on October 12, 2022 @ $141.6028 120 shares on January 4, 2024 @ $197.0267 This reduced my ECL exposure to a relatively insignificant level where it just 'dropped off my radar'. After neglecting ECL [...]
I last reviewed Intercontinental Exchange (ICE) in this February 15, 2026 post at which time the Q4 and FY2025 results were the most current. With the release of Q1 2026 results on April 30, 2026 I revisit this existing holding. Business Overview Part 1 Item 1 in the FY2025 Form 10-K describes ICE's business as follows: [...]
Another month has gone and time for my FFJ Portfolio – April 2026 report. All previous monthly reports are accessible here. Recent Activity Purchases Ecolab (ECL) On April 29 I increased my exposure with the purchase of 100 shares @ $256.845 in a ‘Core’ account in the FFJ Portfolio. S&P Global (SPGI) On April 29 [...]
At the time of my February 11, 2026 S&P Global (SPGI) post, SPGI has just released its Q4 and FY2025 results and FY2026 guidance February 10. In that post I disclose the following purchases through 'Core' accounts in the FFJ Portfolio: 50 shares @ ~$438.5154 on February 6; and 50 shares @ ~$413.085 on February [...]
I last reviewed Moody's (MCO) in this February 25, 2026 post at which time the most current financial information was for Q4 and FY2025. On April 22, 2026, MCO released its Q1 2026 results and revised FY2026 outlook making this an opportune time to revisit this existing holding. Business Overview MCO's two business segments are [...]
I last reviewed Intuitive Surgical (ISRG) in this January 23, 2026 post at which time the most current results were for Q4 and FY2025. With the release of Q1 2026 results following the April 21, 2026 market close this is an opportune time to revisit this existing holding. Business Overview Please reference prior ISRG posts [...]
I last reviewed CME Group (CME) in my March 24, 2026 post. At the time, the most current financial information available was for Q4 and FY2025. On April 22, 2026, CME released its Q1 2026 results thus prompting me to revisit this existing holding in the FFJ Portfolio. Business Overview CME operates a derivatives marketplace [...]
I last reviewed Nasdaq (NDAQ) in this January 30, 2026 post at which time the most current financial information was for Q4 and FY2025. With the release of Q1 2026 results on April 23, 2026, this is an opportune time to revisit this existing holding. Industry Overview The equity exchange business is increasingly competitive and [...]
In my February 13, 2026 post I state that West Pharmaceutical (WST) is the silent winner of the GLP-1 obesity drug boom. Novo Nordisk (NVO) and Eli Lilly (LLY) may grab the headlines. WST, however, is the 'picks and shovels' play in this space. I initiated a 100 share position in a 'Core' account in [...]
